PK/Efficacy Issues
1. What is the role of PK data in the evaluation of new formulations and alternative dosing regimens for approved antiretroviral drugs?
Given the available data, please discuss the strengths and limitations of specific exposure measures, such as AUC and Cmin or other measures, in predicting virologic response.